• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Dementia and Geriatric Cognitive Disorders Extra >Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients
【24h】

Pharmacogenetic Study on the Effect of Rivastigmine on PS2 and APOE Genes in Iranian Alzheimer Patients

机译：利瓦斯的明对伊朗阿尔茨海默病患者PS2和APOE基因影响的药物遗传学研究

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background/Aims: Alzheimer disease (AD) is a complex and genetically heterogeneous disorder, and certain genes such as PS2 and APOE4 contribute to the development of AD. Due to its heterogeneity, AD-predisposing genes could vary in different populations. Moreover, not all AD patients will respond to the same therapy. We specifically investigated the effect ofrivastigmine (Exelon) on PS2 and APOE genes in Iranian AD patients. Methods: A total of 100 AD patients, 67 patients with sporadic AD (SAD) and 33 patients with familial AD (FAD), receiving rivastigmine therapy and 100 healthy controls were studied.PCR-RFLP was used for genotyping of PS2 and APOE. Results: We found a positive association between the PS2 –A allele and SAD patients (pc = 0.01), and the PS2 +A/–A genotype was significantly more frequent in SAD than FAD patients (pc = 0.009). The APOE4 allele was associated with total AD, SAD and FAD (pc = 0.000002). Patients with the PS2 +A/–A genotype and bigenic genotypes of +A/–A·ε3/ε3 and +A/–A·ε3/ε4 were the best responders to Exelon therapy, and those with the PS2 +A/+A and APOE ε3/ε4 genotypes were the worst responders. Conclusion: Our findings suggest that the PS2 and APOE4 alleles and genotypes affect both AD risk and response to rivastigmine therapy.
机译：背景/目的：阿尔茨海默病（AD）是一种复杂的遗传异质性疾病，某些基因（例如PS2和APOE4）有助于AD的发展。由于其异质性，易患AD的基因在不同人群中可能有所不同。此外，并非所有的AD患者都会对同一疗法产生反应。我们专门调查了利伐斯的明（Exelon）对伊朗AD患者PS2和APOE基因的影响。方法：对100例AD患者，67例散发性AD（SAD）和33例家族性AD（FAD）患者进行卡巴拉汀治疗和100例健康对照者进行研究.PCR-RFLP用于PS2和APOE的基因分型。结果：我们发现PS2 –A等位基因与SAD患者之间存在正相关（p c = 0.01），并且SAD中PS2 + A / –A基因型的频率明显高于FAD患者（p c = 0.009）。 APOE4等位基因与总AD，SAD和FAD相关（p c = 0.000002）。 PS2 + A / –A基因型和+ A / –A·eps3; 3 / eps3和+ A / –A·eps3; 3 / eps4的双基因型患者是Exelon治疗的最佳反应者，并且PS2 + A / + A和APOE＆epsi; 3 /＆epsi; 4基因型的患者反应最差。结论：我们的发现表明PS2和APOE4等位基因和基因型影响AD风险和对卡巴拉汀治疗的反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号